Tirzepatide, a new molecule recently approved by the FDA for the treatment of obesity, is a dual receptor agonist acting on the previously mentioned GLP-1 receptors and glucose-dependent insulinotropic peptide (GIP) receptors. The gene discussed is GLP1R; the disease is Obesity.